SynthesisDrug delivery and translational research2024
Extracellular vesicles: powerful candidates in nano-drug delivery systems.
Synthesis in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Beyond Exosomes: Biological Properties, Isolation Challenges, and Functional Redefinition of Non-Vesicular Extracellular Nanoparticles (NVEPs).Biomolecules · 2026Review
- Recent Advances on Extracellular Vesicles: A Natural Nanomaterial for Biomedical Application.Biomimetics (Basel, Switzerland) · 2026Review
- Microvesicles, exosomes and their combinations with cytoplasmic organelles: from their discovery to their innovative roles in clinical medicine.Biology direct · 2026Review
- Exosome-like nanovesicles fromNon-coding RNA research · 2025Article
- The Use of MSCs, iPSCs, and EVs in the Repair of Human MSK Tissues: Is Ultimate Success Dependent on Developing Excellent Implant Materials as Well as Creating an Optimal Environment for Implantation? What Is the Rationale for These Choices?International journal of molecular sciences · 2025Review
- Extracellular Vesicle-Based Drug Delivery Systems in Cancer Therapy.International journal of molecular sciences · 2025Review
- Nanocarriers for cutting-edge cancer immunotherapies.Journal of translational medicine · 2025Review
- Unravelling the complexity of CARPA: a review of emerging advancements in therapeutic strategies.Archives of dermatological research · 2025Review
- Exosome-mediated miRNA delivery: a molecular switch for reshaping neuropathic pain therapy.Frontiers in molecular neuroscience · 2025Review
- Tumor-targeted multifunctional extracellular vesicles as drug carriers for lung cancer therapy.Extracellular vesicles and circulating nucleic acids · 2025Article
- Hydrogel-Based Vaccines: A Promising Approach for Cancer Immunotherapy.International journal of nanomedicine · 2025Review
- Bacterial Outer Membrane Vesicle (OMV)-Encapsulated TiONanomaterials (Basel, Switzerland) · 2024Article
- Current advancements in nanotechnology for stem cells.International journal of surgery (London, England) · 2024Review
- Human plasma derived exosomes: Impact of active and passive drug loading approaches on drug delivery.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems.International journal of nanomedicine · 2024Review
- Extracellular vesicle production: A bidirectional effect in the interplay between host andCurrent research in microbial sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Extracellular vesicles (EVs), which are nanoparticles that are actively released by cells, contain a variety of biologically active substances, serve as significant mediators of intercellular communication, and participate in many processes, in health and pathologically. Compared with traditional nanodrug delivery systems (NDDSs), EVs have unique advantages due to their natural physiological properties, such as their biocompatibility, stability, ability to cross barriers, and inherent homing properties. A growing number of studies have reported that EVs deliver therapeutic proteins, small-molecule drugs, siRNAs, miRNAs, therapeutic proteins, and nanomaterials for targeted therapy in various diseases. However, due to the lack of standardized techniques for isolating, quantifying, and characterizing EVs; lower-than-anticipated drug loading efficiency; insufficient clinical production; and potential safety concerns, the practical application of EVs still faces many challenges. Here, we systematically review the current commonly used methods for isolating EVs, summarize the types and methods of loading therapeutic drugs into EVs, and discuss the latest progress in applying EVs as NDDs. Finally, we present the challenges that hinder the clinical application of EVs.
Indexed as
Identifiers
37581742What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.